Novartis’ Secukinumab Sails Through Advisory Panel, Bodes Well For IL-17 Class
This article was originally published in The Pink Sheet Daily
Executive Summary
Unanimous advisory committee vote positions Novartis’ secukinumab to beat Lilly and Amgen/AstraZeneca competitors to market; panel supportive of Novartis’ preferred dose, letting other dosing issues be further explored post-market.
You may also be interested in...
Sun’s Tildrakizumab Deal: A Calculated Bet?
If approved, tildrakizumab, licensed in globally by Sun Pharma but developed by Merck, will be pitted against established competitors in a crowded market of advanced biologics for plaque psoriasis. But experts believe several advantages can help the top Indian generic firm leap into the wide world of dermatology and anti-inflammatory compounds.
Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into
The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.